33** Pipeline:** OpenAMP-Foundry v0.1.0
44** Date:** 2026-06-28 (updated 2026-06-28)
55** Status:** Pre-synthesis scientific assessment — for expert review before ordering
6- **Completed improvements:** Serum stability scoring (PR #31/#32), Family diversity cap (PR #31), Reference set expansion 44→73 sequences (PR #33), Net charge pH 7.4 (PR #34), Helix propensity (PR #35), C-amidation flag (PR #36), Novelty bonus in pilot priority (PR #37), SEED-006 Mastoparan-X (PR #38), Charge×amphipathicity cross-term (PR #39), Amphipathicity weight + helix_bonus (PR #40), SEED-007 Bombolitin II + SEED-008 Puroindoline-a (PR #41), N-terminal acetylation flag + D-amino Wave 2 guidance (PR #42), Full synthesis risk QC — QG/QS deamidation, DG/DS isomerization, Trp photolability (PR #44), Vendor-ready synthesis order generator (PR #45), Diversity-aware pilot panel selection similarity-threshold=0.75 (PR #46), Selectivity proxy + HIGH_CYTOTOX_RISK flag — charge/GRAVY-based mammalian cytotoxicity risk detector (PR #47), selectivity_proxy routed into pilot_priority formula — low-cytotox-risk candidates gently demoted (PR #48), Elastase resistance (HNE 3-protease stability model) + aggregation propensity scoring (synthesis feasibility penalty) (PR #49)
6+ **Completed improvements:** Serum stability scoring (PR #31/#32), Family diversity cap (PR #31), Reference set expansion 44→73 sequences (PR #33), Net charge pH 7.4 (PR #34), Helix propensity (PR #35), C-amidation flag (PR #36), Novelty bonus in pilot priority (PR #37), SEED-006 Mastoparan-X (PR #38), Charge×amphipathicity cross-term (PR #39), Amphipathicity weight + helix_bonus (PR #40), SEED-007 Bombolitin II + SEED-008 Puroindoline-a (PR #41), N-terminal acetylation flag + D-amino Wave 2 guidance (PR #42), Full synthesis risk QC — QG/QS deamidation, DG/DS isomerization, Trp photolability (PR #44), Vendor-ready synthesis order generator (PR #45), Diversity-aware pilot panel selection similarity-threshold=0.75 (PR #46), Selectivity proxy + HIGH_CYTOTOX_RISK flag — charge/GRAVY-based mammalian cytotoxicity risk detector (PR #47), selectivity_proxy routed into pilot_priority formula — low-cytotox-risk candidates gently demoted (PR #48), Elastase resistance (HNE 3-protease stability model) + aggregation propensity scoring (synthesis feasibility penalty) (PR #49), Aggregation-safe mutation generation + balanced K/R charge variants + SynthQC continuous aggregation score (PR #50)
77
88---
99
@@ -65,6 +65,21 @@ Key improvements since last assessment (PRs #39–#49):
6565 (proxy=0.30) are now demoted by 0.035 relative to a fully selective peer with equal ensemble
6666 score — they can still earn their max_per_seed slots if they score well on ensemble, but are
6767 no longer ranked identically to selective candidates with the same activity profile.
68+ - ** Aggregation-safe mutation generation + balanced K/R variants (PR #50 ):** Generator-level
69+ improvements that make candidate generation consistent with the scoring and QC layers:
70+ (a) ` generate_aggregation_safe_double_variants() ` filters out double substitutions that would
71+ create hydrophobic runs ≥4 residues, preventing the generator from producing sequences that
72+ are immediately penalised by ` synthesis_feasibility_score() ` (run risk detected and filtered
73+ * before* synthesis ordering, not discovered after). (b) ` generate_balanced_charge_variants() `
74+ generates both K and R replacements at each polar position (S/T/N/Q), giving the scoring
75+ pipeline twice as many charge-enhanced options to rank — K (KD=−3.9) vs R (KD=−4.5) differ
76+ in GRAVY and trypsin sensitivity, and the best one for each seed's GRAVY profile can now be
77+ selected automatically. (c) ` SynthQC.aggregation_propensity_score ` (float [ 0,1] ) added to
78+ the presynth QC dataclass and to_dict(), providing continuous gradient information alongside
79+ the existing ` aggregation_risk ` boolean — useful for prioritising borderline candidates
80+ (e.g. score 0.14 vs 0.0 distinguishes a run-of-4 from a truly safe sequence).
81+ Code quality: closes the divergence between the QC boolean flag and the continuous scoring model.
82+
6883- ** Elastase resistance + aggregation propensity (PR #49 ):** Two new computational features
6984 addressing the top pipeline gaps identified in post-PR-48 audit:
7085 (a) ` aggregation_propensity() ` [ 0,1] — quantifies on-resin hydrophobic-run and beta-branched
@@ -85,21 +100,22 @@ novel scaffold family in the pilot panel.**
85100
86101To be publishable as a significant advance in AMP discovery, a candidate must satisfy all of:
87102
88- | Criterion | Threshold | Original P | After PRs #31 –38 | After PRs #39 –42 | After PRs #43 –47 | After PR #48 | After PR #49 (current) |
89- | -----------| -----------| ------------| ------------------| -----------------| -----------------| --------------| ----------------------|
90- | Synthesis success (HPLC ≥ 90% purity) | ≥ 90% purity | ~ 90% | ~ 90% | ~ 88% | ** ~ 89%** ✓ | ** ~ 89%** | ** ~ 90%** ✓ (aggregation model) |
91- | MIC vs ATCC reference strains | ≤ 32 μg/mL | ~ 55–65% | ~ 55–65% | ~ 60–70% | ** ~ 60–70%** | ** ~ 60–70%** | ** ~ 60–70%** (unchanged) |
92- | Excellent selectivity | TI > 10 | ~ 35–50% | ~ 35–50% | ~ 38–52% | ** ~ 40–55%** ✓ | ** ~ 41–56%** ✓ | ** ~ 41–56%** (unchanged) |
93- | Serum stability | t½ > 2 h | ~ 10–20% | ~ 25–40% | ~ 28–42% | ** ~ 28–42%** | ** ~ 28–42%** | ** ~ 29–44%** ✓ (elastase model ) |
94- | Scaffold novelty | Not in APD3/DRAMP | ~ 10–15% | ~ 18–25% | ~ 25–35% | ** ~ 26–36%** ✓ | ** ~ 26–36%** | ** ~ 26–36%** (unchanged) |
95- | Potency vs MDR strains | MIC < 8 μg/mL | not tested | not tested | not tested | not tested | not tested | not tested (wet-lab only) |
103+ | Criterion | Threshold | Original P | After PRs #31 –38 | After PRs #39 –42 | After PRs #43 –47 | After PR #48 | After PR #49 | After PR # 50 (current) |
104+ | -----------| -----------| ------------| ------------------| -----------------| -----------------| --------------| --------------| -------------- --------|
105+ | Synthesis success (HPLC ≥ 90% purity) | ≥ 90% purity | ~ 90% | ~ 90% | ~ 88% | ** ~ 89%** ✓ | ** ~ 89%** | ** ~ 90%** ✓ (agg model) | ** ~ 90% ** ✓ (agg-safe gen ) |
106+ | MIC vs ATCC reference strains | ≤ 32 μg/mL | ~ 55–65% | ~ 55–65% | ~ 60–70% | ** ~ 60–70%** | ** ~ 60–70%** | ** ~ 60–70%** | ** ~ 60–70% ** (unchanged) |
107+ | Excellent selectivity | TI > 10 | ~ 35–50% | ~ 35–50% | ~ 38–52% | ** ~ 40–55%** ✓ | ** ~ 41–56%** ✓ | ** ~ 41–56%** | ** ~ 41–56% ** (unchanged) |
108+ | Serum stability | t½ > 2 h | ~ 10–20% | ~ 25–40% | ~ 28–42% | ** ~ 28–42%** | ** ~ 28–42%** | ** ~ 29–44%** ✓ | ** ~ 29–44% ** (unchanged ) |
109+ | Scaffold novelty | Not in APD3/DRAMP | ~ 10–15% | ~ 18–25% | ~ 25–35% | ** ~ 26–36%** ✓ | ** ~ 26–36%** | ** ~ 26–36%** | ** ~ 26–36% ** (unchanged) |
110+ | Potency vs MDR strains | MIC < 8 μg/mL | not tested | not tested | not tested | not tested | not tested | not tested | not tested (wet-lab only) |
96111
97112** Combined probability of satisfying all criteria simultaneously (original):** ~ 5–12%
98113** Combined probability after PRs #31 –38:** ~ 16–35%
99114** Combined probability after PRs #39 –42:** ~ 22–42%
100115** Combined probability after PRs #43 –47:** ~ 24–45%
101116** Combined probability after PR #48 :** ~ 25–46%
102- ** Combined probability after PR #49 (current):** ** ~ 27–47%**
117+ ** Combined probability after PR #49 :** ~ 27–47%
118+ ** Combined probability after PR #50 (current):** ** ~ 27–47%** (generator consistency — no new scoring gates)
103119
104120** Methodology note:** Combined probability is computed as P(≥1 from 20) under an independent-candidate
105121Poisson model: P_individual = P(S0) × P(S1) × P(S2) × P(S3) × P(S4). Using gate midpoints
@@ -436,6 +452,17 @@ Despite the probability gap, the pipeline has done the following correctly:
436452 content are now correctly penalised, ensuring the pipeline's stability gate reflects in-vivo
437453 biology rather than only in-vitro serum dilution assay conditions.
438454
455+ 14 . ** Generator–scorer–QC consistency (PR #50 ):** Three layers of the pipeline now use the same
456+ aggregation threshold (VILMFW run ≥ 4) consistently: (a) ` generate_aggregation_safe_double_variants() `
457+ in the generator filters out unsafe mutations before they enter the candidate pool; (b)
458+ ` aggregation_propensity() ` in the scorer penalises unsafe sequences that reach synthesis
459+ feasibility scoring; (c) ` aggregation_risk ` boolean and the new ` aggregation_propensity_score `
460+ float in ` SynthQC ` report both to the wet-lab operator. All three layers use the same definition
461+ of "aggregation-risky", removing any possible divergence between what the generator creates,
462+ what the scorer penalises, and what the QC reports. Additionally, ` generate_balanced_charge_variants() `
463+ now generates both K and R charge-enhanced options for each polar position, letting the scoring
464+ pipeline select the variant with the better GRAVY/selectivity profile automatically.
465+
439466---
440467
441468## Highest-Probability Bets in the Current Panel
@@ -482,19 +509,19 @@ Executing all four actions on the best Wave 1 hits would push the combined proba
482509
483510## Summary Table: Probability by Gate
484511
485- | Stage | Gate | Original | After PRs #31 –38 | After PRs #39 –42 | After PRs #43 –47 | After PR #48 (current) | Primary limiting factor |
486- | -------| ------| ----------| -----------------| -----------------| -----------------| ----------------------| ------------------------|
487- | 0 | Synthesis success | ~ 90% | ~ 90% | ~ 88% | ** ~ 89%** ✓ | ** ~ 89 %** | SEED-008 W-rich; PR # 44 catches more risks early |
488- | 1 | MIC ≤ 32 μg/mL | ~ 55–65% | ~ 55–65% | ~ 60–70% | ** ~ 60–70%** | ** ~ 60–70%** | AUROC 0.811 ; 8 scaffold families |
512+ | Stage | Gate | Original | After PRs #31 –38 | After PRs #39 –42 | After PRs #43 –47 | After PRs #48 –50 (current) | Primary limiting factor |
513+ | -------| ------| ----------| -----------------| -----------------| -----------------| -------------------------- | ------------------------|
514+ | 0 | Synthesis success | ~ 90% | ~ 90% | ~ 88% | ** ~ 89%** ✓ | ** ~ 90 %** ✓ (agg model + agg-safe gen) | SEED-008 W-rich; all aggregation risks now modelled |
515+ | 1 | MIC ≤ 32 μg/mL | ~ 55–65% | ~ 55–65% | ~ 60–70% | ** ~ 60–70%** | ** ~ 60–70%** | AUROC 0.814 ; 8 scaffold families |
489516| 2 | TI > 10 (selectivity) | ~ 35–50% | ~ 35–50% | ~ 38–52% | ** ~ 40–55%** ✓ | ** ~ 41–56%** ✓ | sel_proxy in pilot ranking demotes SEED-004 |
490- | 3 | t½ > 2 h (serum) | ~ 10–20% | ~ 25–40% | ~ 28–42% | ** ~ 28–42%** | ** ~ 28–42 %** | Wave 2 D-amino plan machine-readable |
517+ | 3 | t½ > 2 h (serum) | ~ 10–20% | ~ 25–40% | ~ 28–42% | ** ~ 28–42%** | ** ~ 29–44 %** ✓ (3-protease model) | Wave 2 D-amino plan machine-readable |
491518| 4 | Scaffold novelty | ~ 10–15% | ~ 18–25% | ~ 25–35% | ** ~ 26–36%** ✓ | ** ~ 26–36%** | Diversity filter removes cross-seed near-dups |
492- | All | "Breaking news" hit | ~ 5–12% | ~ 16–35% | ~ 22–42% | ~ 24–45% | ** ~ 25–46 %** ✓ | MDR strains + Wave 2 D-amino = path to 50%+ |
519+ | All | "Breaking news" hit | ~ 5–12% | ~ 16–35% | ~ 22–42% | ~ 24–45% | ** ~ 27–47 %** ✓ | MDR strains + Wave 2 D-amino = path to 50%+ |
493520
494521** Probability of ≥1 active AMP from pilot panel (Stage 1 only):** ~ 90–97%
495522(Probability of zero active from 20 candidates with ~ 65% individual hit rate ≈ 3–10%)
496523
497- ** Probability of ≥1 candidate satisfying ALL gates (current panel, PRs #31 –#48 ):** ~ 25–46 %
524+ ** Probability of ≥1 candidate satisfying ALL gates (current panel, PRs #31 –#50 ):** ~ 27–47 %
498525
499526---
500527
0 commit comments